Lepodisiran Sodium for atherosclerosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Mar 2024: Trial registered, NCT06292013
  2. 5 Mar 2024: Trial started, NCT06292013

The trials

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

State
Under way
Phase
Phase 3
People
17,300 planned
Started
5 Mar 2024
Primary completion
Mar 2029
Arms
Lepodisiran Sodium
Results
None posted
  1. 4 Mar 2024: Trial registered
  2. 5 Mar 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.